The present invention relates to the use of type I polymerized collagen in Covid-19 positive patients and to an intramuscular dosing regimen every 12 h for 3 days and then every 24 h for 4 days in patients with mild to moderate Covid-19 disease, or an intramuscular dosing regimen every 12 h for 7 days in patients with severe to semi-critical illness due to Covid-19. In addition, the clinical evolution of each patient was analyzed individually (FIGS. 13 to 17 and 20 to 21) and in groups (FIGS. 18 and 19), taking into account the following parameters: percentage of SpO2, temperature, heart rate, respiratory rate, cough intervals, chest pain, headache, dyspnea, odynophagia, anosmia, loss of sense of taste, presence of arthralgia and myalgia, and clinical improvement was documented in all cases.
The present invention relates to the use of type I polymerized collagen in Covid-19 positive patients and to an intramuscular dosing regimen every 12 h for 3 days and then every 24 h for 4 days in patients with mild to moderate Covid-19 disease, or an intramuscular dosing regimen every 12 h for 7 days in patients with severe to semi-critical illness due to Covid-19. In addition, the clinical evolution of each patient was analyzed individually (Figures 13 to 17 and 20 to 21) and in groups (Figures 18 and 19), taking into account the following parameters: percentage of SpO2, temperature, heart rate, respiratory rate, cough intervals, chest pain, headache, dyspnea, odynophagia, anosmia, loss of sense of taste, and presence of arthralgia and myalgia; clinical improvement was documented in all cases.
The present invention relates to the use of type I polymerized collagen in Covid-19 positive patients and to an intramuscular dosing regimen every 12 h for 3 days and then every 24 h for 4 days in patients with mild to moderate Covid-19 disease, or an intramuscular dosing regimen every 12 h for 7 days in patients with severe to semi-critical illness due to Covid-19. In addition, the clinical evolution of each patient was analyzed individually (Figures 13 to 17 and 20 to 21) and in groups (Figures 18 and 19), taking into account the following parameters: percentage of SpO2, temperature, heart rate, respiratory rate, cough intervals, chest pain, headache, dyspnea, odynophagia, anosmia, loss of sense of taste, and presence of arthralgia and myalgia; clinical improvement was documented in all cases.
The instant invention relates to a composition based on collagen-polyvinylpyrrolidone and perhydrosqualene for filling, through intracutaneous route, minor skin depressions to improve its aspect without producing a negative immune reaction or rejection of extraneous body, to a process for preparing it and to its use for the prevention and treatment of minor skin depressions through a temporary mechanical effect to prevent thus the encapsulation of the substance, because depending, among various factors, on the time, some compositions can generate a reaction against the extraneous body deriving in an inflammation of the treated region and fibrosis. The composition of the instant invention is characterized because it is prepared at a controlled alkaline pH and forms a stable, foamless emulsion.
The present invention concerns a composition based on collagen-polyvinylpyrrolidone and perhydrosqualene for filling by intracutaneous delivery route minor depressions of the skin in order to enhance the appearance thereof without causing a negative immune reaction or rejection of the extraneous body, a method for preparing the composition and the use thereof in the prevention and treatment of minor depressions in the skin by means of a temporary mechanical effect thereby avoiding the encapsulation of the substance, since depending among various factors on time, some compositions eventually cause a reaction to the extraneous body, leading to inflammation of the treated area and fibrosis. The composition as per the invention has the characteristic of being prepared to a controlled alkaline PH and forms a stable emulsion without foam.
The invention relates to a chronic articular inflammation-modulating composition which uses collagen-polyvinylpyrrolidone. Collagen turnover is modulated using collagen-PVP in patients with rheumatoid arthritis and osteoarthritis, since the biocomplex negatively regulates collagenolytic activity and increases the content of type III collagen and TIMP-1 to levels similar to those observed in normal synovia. In this way, the chronic inflammatory process is altered by the collagen-PVP, as described above, owing to the negative regulation of IL-1, the TNF- of IL-8 and the adhesion molecules, since said molecules can induce the expression and activation of collagenolytic enzymes, as well as the proliferation and migration of synovial cells by means of the adhesive mechanisms including the adhesion molecules, and the induction and activation of Cox-1. In addition to cellular anchoring, the interaction of the extracellular matrix integrins generates signals which regulate the expression of MMPs, suggesting that the adhesion molecules can also play a part in tissue destruction associated with rheumatoid arthritis. Moreover, the decrease in the synthesis of TNF- and IL-1 appears to stimulate the cell death of synoviocytes by means of apoptosis, which, in turn, seems to contribute to the inhibition of the proliferation of synovial cells, the formation of pannus and the destruction of the articular tissue.
